Navigation Links
International Movement Disorder Specialists Receive New Information,About the Use of Once-Daily Azilect in the Treatment of Parkinson's,Disease

Results presented at the Movement Disorder Society's 11th International Congress in Istanbul, Turkey

KANSAS CITY, Mo., June 08, 2007 /PRNewswire-FirstCall/ -- New information on the use of AZILECT(R) (rasagiline tablets) for the treatment of Parkinson's disease (PD) was reported this week at The Movement Disorder Society's congress in Istanbul, Turkey. Once-daily AZILECT was approved by the FDA May 17, 2006, for the treatment of the signs and symptoms of PD, both as initial monotherapy and as adjunct therapy to levodopa.

AZILECT(R) Monotherapy Demonstrates Benefits in Early PD Regardless of Disease Duration

Dr. John Bertoni, M.D., Ph.D., provided the results of a new post-hoc analysis of the 26-week, multicenter, randomized, double-blind TEMPO study, that included 404 patients who received once-daily AZILECT 1mg, 2mg, or placebo. This analysis revealed that AZILECT once-daily as monotherapy provided a consistent beneficial effect on the symptoms of PD regardless of the duration of the disease at the time treatment was started. AZILECT 1 mg/day significantly improved UPDRS-Total score compared to placebo in both the < 1-year stratum (-0.52 vs 3.33; p<0.001) and the greater than or equal to 1-year stratum (0.81 vs 4.76; p<0.01). "The time to diagnosis and initial treatment is different for every patient," said Dr. Bertoni. "Demonstrating that AZILECT monotherapy has a beneficial effect, regardless of disease duration, is important when considering it as a treatment option for patients with PD."

AZILECT(R) Clinical Experience When Given Concomitantly with Antidepressants

Dr. Michel Panisset, M.D., CHUM - Hotel-Dieu de Montreal, Quebec, reported on an evaluation of the records of 1,361 patients who had taken AZILECT for the treatment of Parkinson's disease in controlled clinical trials to assess the safety of combining antidepressant therapy with AZILECT. Three hundred and twenty three (
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

Post Your Comments:
(Date:11/25/2009)...25/PRNewswire/-- ChemoCentryx,Inc.,announcedtoday...-1(theProspectiveRandomizedOralTherapyEvaluationin...atientswithmoderate-to-severeCrohn,sdiseasedemonst...bilityprofile.Thestudydemonstratedevidenceofclinic...asa70-pointdecreaseintheCrohn,sDiseaseActivityInde...
(Date:11/24/2009)...wswire-FirstCall/--QuestDiagnosticsIncorporated(NY...ting,informationandservices,announcedthatitissched...nferenceinNewYorkCity.Thepresentationisscheduledfo..., Duringtheconference,thecompanywillreaffirmits2...ngincometoexceed18%ofrevenues,anddilutedearningspe...
(Date:11/24/2009)...swire/--Inadditiontofamily,friendsandhealth,cancer...erThanksgivinggratitudelist. ,, "Theyheardthefa...idofMonday,sverdictstotaling$103millionindamagesag...,000womennationwidewhohavesuedWyethandPfizerpharma...dPrempro.Wisneskiandtheothervictimsofhormonetherap...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Maryland Woman Thankful for Wyeth Verdicts 2Michigan IT Companies Helping the University of Miami Center for Patient Safety Tackle a Leading Cause of Death Using an RTLS Solution to Monitor Staf 53131 1Michigan IT Companies Helping the University of Miami Center for Patient Safety Tackle a Leading Cause of Death Using an RTLS Solution to Monitor Staf 53131 2Michigan IT Companies Helping the University of Miami Center for Patient Safety Tackle a Leading Cause of Death Using an RTLS Solution to Monitor Staf 53131 3Consumer Alert 3A Minimally Invasive Cosmetic Procedures Should Not Be Taken Lightly 53128 1Consumer Alert 3A Minimally Invasive Cosmetic Procedures Should Not Be Taken Lightly 53128 2Consumer Alert 3A Minimally Invasive Cosmetic Procedures Should Not Be Taken Lightly 53128 3Consumer Alert 3A Minimally Invasive Cosmetic Procedures Should Not Be Taken Lightly 53128 4Consumer Alert 3A Minimally Invasive Cosmetic Procedures Should Not Be Taken Lightly 53128 5Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin 4794 1Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin 4794 2Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin 4794 3Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin 4794 4
...BN,ImmunoTherapeutics, Inc. today provided updated...ncer vaccine, MVA-BN(R)-HER2, in development as,th...umours over-express HER2.,The study met its primar...n,immune response. Evidence of vaccine-induced ant...ly 70% of evaluated patients. , Clinically, th...
...ternational team of,researchers has evaluated the ...tis of the knee, and the results have been publish...al "Osteoarthritis and Cartilage".,The researchers...ess of,various osteoarthritis treatments. After si...received Orthokine therapy experienced significant...
Other Medicine Technology:BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 2BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine 3New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years 2
(Date:11/27/2009)... Three new interactive anatomy e...s & Wilkins expand health sciences learning op... Durham, NC (Vocus) November 27, 200...; Wilkins (LWW), a division of Wolters Kluwer Heal...anatomy education apps on the App Store. Clemente&...
(Date:11/26/2009)... that,s too big or too heavy can lead to strains o... News) -- There may be nothing wrong with stuffing...ant to do the same thing with your suitcase as you...ple were treated in 2008 in U.S. hospital emergenc...al facilities for luggage-related injuries, such a...
(Date:11/26/2009)... Benton Communications announces...owth system for retailers struggling to make an ec...) November 26, 2009 -- Flu fears is the type of ch...e emergency room, according to Dr. David Benton, b...ased business growth system – The Rfactor I...
(Date:11/25/2009)... TORONTOandCALGARY,Nov.25/PRNewswire/-SentinelleMe...maging(MRI)coilsandsoftwareandCalgaryScientificInc...aveintroducedawebversionofAegis(TM)Breast4DAdvance...aceisthefirsttrulyzero-footprintWebclientbasedmedi...ureWeb(TM)platformallowsforzero-footprintaccess-re...
(Date:11/25/2009)... SANFRANCISCO,Nov.25/PRNewswire/--TheBayAreaAirQua...nter Spare the Air Alert forThursday...irelogsoranyothersolidfuel,bothindoorsandoutdoors....airqualitytomorrow,"saidJackBroadbent,executiveoff...orespectthehealthoftheirneighborsandfellowcommunit...
Breaking Medicine News(10 mins):Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2
...ay help the fight against increasing obesity, acco...y, mens health and ageing Professor Gary Wittert. ...els of obesity in Australian men and that this has...lood vessels to the heart are affected by obesity ...
...ng care and care management,company, BRENTWOOD, T...ed provider of care management for the frail elder...ealth care policy expert,Stuart Altman has been ap...erly, the chronically ill,and those with disabilit...
... than those who only finish high school, study fin...-- Life expectancy in the United States is on the ...years of education, a new study finds. , In fact, ...on, life expectancy is 75. , "If you look in recen...
...Holdings,Inc. (OTC Bulletin Board: IFMX) is please...Partners to provide Capital Markets Advisory Servi...ork City, is a 16 year old firm,that specializes i...ons, exchange listings, Sarbanes Oxley requirement...
... and treat autism during the first few m... GAINESVILLE, Fla., March 11 Medical experts agr...y begun, the greater the chance a,child can be hel... on social interaction, language acquisition, and,...
... the theme of this year,s conference;, learn about...) principles, in the field of electromagnetic rad...people who are creating healthy buildings every da...n my patient,s home be making them sick?" As a bui...
Other Medicine News:Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 2Health News:Stuart Altman, Ph.D. Joins INSPIRIS Board of Directors 3Health News:Life Expectancy Tied to Education 2Health News:Life Expectancy Tied to Education 3Health News:InforMedix Retains Murdock Capital Partners 2Health News:InforMedix Retains Murdock Capital Partners 3Health News:InforMedix Retains Murdock Capital Partners 4Health News:Autism Awareness Month - New Hope for Detecting/Reversing Autism in Infants 2Health News:2008 Building Biology(R) Conference, April 19th & 20th, Hotel Radisson at Opryland, Nashville, Tennessee 2Health News:2008 Building Biology(R) Conference, April 19th & 20th, Hotel Radisson at Opryland, Nashville, Tennessee 3
QualCraft™ Metal Oval W/Shield
Radiation Readers, Bifocals - Carbon
Regular Barrier
Porta-Shield
Medicine Products: